TRCT
KRYS icon

Tower Research Capital (TRC)’s Krystal Biotech KRYS Stock Holding History

Tower Research Capital (TRC)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$599K Buy
2,318
+632
+37% +$168K 0.02% 799
2025
Q4 		$416K Buy
1,686
+693
+70% +$146K 0.01% 935
2025
Q3 		$175K Sell
993
-2,005
-67% -$300K ﹤0.01% 1573
2025
Q2 		$412K Buy
2,998
+2,268
+311% +$333K 0.01% 1148
2025
Q1 		$132K Sell
730
-6,269
-90% -$1.05M ﹤0.01% 1616
2024
Q4 		$1.1M Buy
6,999
+6,912
+7,945% +$1.23M 0.02% 581
2024
Q3 		$15.8K Sell
87
-2,115
-96% -$408K ﹤0.01% 3394
2024
Q2 		$404K Buy
2,202
+565
+35% +$94.9K 0.01% 1513
2024
Q1 		$291K Buy
1,637
+381
+30% +$52.9K 0.01% 1180
2023
Q4 		$156K Sell
1,256
-350
-22% -$38.8K ﹤0.01% 2290
2023
Q3 		$186K Buy
1,606
+911
+131% +$111K 0.01% 1475
2023
Q2 		$81.6K Sell
695
-261
-27% -$26.6K ﹤0.01% 2195
2023
Q1 		$77K Buy
956
+571
+148% +$44.9K ﹤0.01% 2107
2022
Q4 		$31K Sell
385
-3,092
-89% -$230K ﹤0.01% 2718
2022
Q3 		$242K Buy
3,477
+710
+26% +$51.3K ﹤0.01% 1732
2022
Q2 		$181K Sell
2,767
-359
-11% -$22.3K ﹤0.01% 1838
2022
Q1 		$208K Sell
3,126
-2,473
-44% -$154K ﹤0.01% 1689
2021
Q4 		$391K Buy
5,599
+3,189
+132% +$186K 0.01% 1282
2021
Q3 		$126K Buy
2,410
+558
+30% +$33K ﹤0.01% 2204
2021
Q2 		$126K Buy
1,852
+734
+66% +$51.2K ﹤0.01% 2235
2021
Q1 		$87K Buy
1,118
+474
+74% +$34.5K ﹤0.01% 2691
2020
Q4 		$39K Buy
644
+321
+99% +$16K ﹤0.01% 3344
2020
Q3 		$14K Sell
323
-3,349
-91% -$145K ﹤0.01% 3964
2020
Q2 		$152K Buy
+3,672
New +$177K 0.01% 2057
2020
Q1 		– Sell
-1,180
Closed -$65K – 3506
2019
Q4 		$65K Buy
1,180
+497
+73% +$24.4K 0.01% 1173
2019
Q3 		$23K Sell
683
-1,112
-62% -$49.7K ﹤0.01% 2372
2019
Q2 		$72K Buy
+1,795
New +$58.7K ﹤0.01% 1360
2019
Q1 		– Sell
-1,140
Closed -$24K – 4053
2018
Q4 		$24K Sell
1,140
-1,487
-57% -$31.1K ﹤0.01% 1794
2018
Q3 		$46K Buy
+2,627
New +$44.1K ﹤0.01% 1804

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s KRYS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Krystal Biotech (KRYS) stake by 37% in Q1 2026, buying an estimated $168K and bringing the position to 2,318 shares worth $599K. The position accounts for 0.02% of the portfolio, ranked #799.

Tower Research Capital (TRC) first reported a position in KRYS in Q3 2018 and has held it in 29 quarters since. The position peaked at $1.1M in Q4 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Tower Research Capital (TRC) held 2,318 shares of Krystal Biotech worth $599K as of Q1 2026.
  • Tower Research Capital (TRC) bought 632 Krystal Biotech shares in Q1 2026, an estimated $168K.
  • Krystal Biotech made up 0.02% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #799 holding.
  • Tower Research Capital (TRC) first reported a position in Krystal Biotech in Q3 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Krystal Biotech position peaked at $1.1M in Q4 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.